Firm
Regulatory changes and damages risks are prompting Canadian firms and clients to opt for settlements in generic and biosimilar cases
A new claim filed by Ericsson, and a request for access to documents, were also among recent developments
Matthew Grady of Wolf Greenfield says AI presents an opportunity in patent practice for stronger collaboration between in-house and outside counsel
Discussion hosted by Bird & Bird partners also hears that UK courts’ desire to determine FRAND rates could see the jurisdiction penalised in a similar way to China
Sponsored
Sponsored
-
Sponsored by RNA, Technology and IP AttorneysThere are strategic intellectual property considerations at every stage of a brand’s development. Ranjan Narula, Aditi Roy Chowdhury, and Simran Singh of RNA, Technology and IP Attorneys outline how startups can take a phased approach -
Sponsored by Adams & AdamsMohamed Jameel Hamid and Alicia van der Walt of Adams & Adams unpack the African Continental Free Trade Area agreement, explain its impact on intellectual property, and outline practical strategies for brand owners across Africa
-
Sponsored by Cabinet M OproiuRaluca Vasilescu of Cabinet M Oproiu concludes a series on the use of artificial intelligence in patent practice by analysing how AI assistants affect the skilled reader’s perspective and the drafting of patent applications
-
Sponsored by Bird & BirdAnne-Raphaëlle Aubry of Bird & Bird explains how Section 1782 and Rule of Procedure 190 offer different pathways for cross-border evidence gathering in European patent disputes, highlighting timing, scope, and strategic considerations for litigants
-
Sponsored by Becerril, Coca & BecerrilMonica Sánchez of Becerril, Coca & Becerril explains how the Mexican intellectual property framework, including compulsory licences and the Bolar clause, works alongside emerging technologies to balance pharmaceutical innovation with public health access
-
Sponsored by Wanhuida Intellectual PropertyXiaoping Wu of Wanhuida Intellectual Property explains how the CNIPA’s recent invalidation of a sustained-release patent illustrates key considerations in assessing inventive step for pharmaceutical formulation patents
